Quanterix Corporation (QTRX) Current Ratio
- Current ratio · latest quarter: Value 3.40×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.40× | Current assets / current liabilities. $171.05M ÷ $50.37M ≈ 3.40× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 171.05M USD | Assets, Current |
| Current obligations | 50.37M USD | Liabilities, Current |
| Cash and equivalents | 44.17M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 49.36M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 22.34M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 47.60M USD | Inventory, Net |
| Payables | 8.89M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $171.05M | $50.37M | $44.17M | $49.36M | $22.34M | $47.60M | $8.89M | (m) | 3.40× |
| 2026-03-31 | $185.72M | $49.91M | $36.18M | $63.08M | $26.78M | $50.96M | $8.66M | (m) | 3.72× |
| 2025-12-31 | $212.26M | $74.76M | $29.84M | $88.39M | $29.97M | $54.76M | $13.57M | (m) | 2.84× |
| 2025-09-30 | $233.28M | $77.35M | $38.30M | $96.51M | $33.03M | $54.96M | $10.63M | (m) | 3.02× |
| 2025-06-30 | $322.12M | $48.20M | $132.90M | $128.28M | $23.55M | $30.14M | $9.12M | (m) | 6.68× |
| 2025-03-31 | $335.00M | $40.40M | $76.51M | $190.37M | $28.26M | $31.03M | $6.73M | (m) | 8.29× |
| 2024-12-31 | $363.59M | $42.01M | $56.71M | $232.41M | $32.14M | $32.77M | $6.95M | (m) | 8.66× |
| 2024-09-30 | $366.96M | $36.45M | $29.34M | $264.18M | $31.09M | $32.97M | $6.38M | (m) | 10.07× |
| 2024-06-30 | $370.50M | $38.14M | $47.00M | $249.85M | $31.78M | $33.19M | $7.27M | (m) | 9.71× |
| 2024-03-31 | $369.35M | $32.76M | $45.28M | $256.64M | $29.28M | $28.63M | $3.98M | (m) | 11.28× |
| 2023-12-31 | $382.10M | $38.98M | $174.42M | $6.89M | $25.41M | $26.12M | $5.05M | (m) | 9.80× |
| 2023-09-30 | $381.87M | $35.90M | $201.26M | $126.45M | $24.08M | $20.86M | $4.79M | (m) | 10.64× |
| 2023-06-30 | $379.12M | $32.61M | $329.52M | (m) | $24.37M | $18.33M | $3.24M | (m) | 11.63× |
| 2023-03-31 | $375.47M | $27.48M | $329.35M | (m) | $22.55M | $16.63M | $2.58M | (m) | 13.66× |
| 2022-12-31 | $381.52M | $31.35M | $338.74M | $0.00 | $19.02M | $16.96M | $3.84M | (m) | 12.17× |
| 2022-09-30 | $386.19M | $28.92M | $343.74M | (m) | $18.33M | $18.04M | $2.11M | (m) | 13.35× |
| 2022-06-30 | $413.90M | $36.73M | $361.55M | (m) | $19.68M | $22.68M | $5.91M | (m) | 11.27× |
| 2022-03-31 | $435.46M | $31.75M | $374.54M | (m) | $22.62M | $24.43M | $4.19M | (m) | 13.71× |
| 2021-12-31 | $448.95M | $36.98M | $396.46M | (m) | $23.79M | $22.19M | $9.21M | (m) | 12.14× |
| 2021-09-30 | $459.43M | $31.19M | $410.75M | (m) | $18.43M | $22.79M | $5.82M | $1.99M | 14.73× |
| 2021-06-30 | $476.44M | $37.67M | $430.78M | (m) | $15.43M | $21.23M | $6.86M | $7.72M | 12.65× |
| 2021-03-31 | $482.44M | $36.49M | $442.67M | (m) | $14.94M | $17.04M | $6.50M | $7.69M | 13.22× |
| 2020-12-31 | $219.60M | $39.80M | $181.58M | (m) | $17.18M | $14.86M | $6.80M | $7.67M | 5.52× |
| 2020-09-30 | $214.93M | $28.09M | $173.16M | (m) | $26.26M | $13.27M | $5.96M | $5.74M | 7.65× |
| 2020-06-30 | $114.24M | $18.90M | $88.81M | (m) | $9.53M | $13.79M | $4.88M | (m) | 6.05× |
| 2020-03-31 | $122.54M | $18.01M | $96.36M | (m) | $12.06M | $11.39M | $4.72M | (m) | 6.80× |
| 2019-12-31 | $132.66M | $19.83M | $109.16M | (m) | $10.91M | $10.46M | $5.78M | $75.00K | 6.69× |
| 2019-09-30 | $138.70M | $18.22M | $113.33M | (m) | $11.91M | $11.16M | $4.25M | $75.00K | 7.61× |
| 2019-06-30 | $92.39M | $17.02M | $72.03M | (m) | $9.13M | $8.85M | $3.51M | $75.00K | 5.43× |
| 2019-03-31 | $51.52M | $16.60M | $33.97M | (m) | $7.30M | $7.74M | $3.79M | $75.00K | 3.10× |
| 2018-12-31 | $59.50M | $18.13M | $44.43M | (m) | $6.79M | $5.95M | $5.11M | (m) | 3.28× |
| 2018-09-30 | $62.70M | $15.24M | $51.42M | (m) | $4.65M | $5.38M | $3.87M | (m) | 4.11× |
| 2018-06-30 | $70.70M | $23.36M | $60.47M | (m) | $3.59M | $5.49M | $3.12M | $7.61M | 3.03× |
| 2018-03-31 | $76.62M | $22.79M | $65.23M | (m) | $4.66M | $5.33M | $2.96M | $8.46M | 3.36× |
| 2017-12-31 | $89.25M | $19.71M | $79.68M | (m) | $5.60M | $3.57M | $3.55M | $5.04M | 4.53× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |